Clinical Trial Search

Primary: Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — 17; 2 Participants

Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009

Primary: Number of Participants Experiencing Solicited Adverse Events (AEs) Through 48 Hours Post-infusion — 7; 4; 3; 3 Participants

Primary: Viral Confirmation — 6; 0 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants

Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…

Primary: Average Diarrhea Duration. — 43.4; 54.7 hours — p=0.004

Primary: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer…

Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants

Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants

Primary: Estimating the Incidence of Rotavirus Gastroenteritis Associated Hospitalization in Children < 5 Years of Age — 428 Participants

Primary: Virus Infection — 8; 18 Participants

Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants

Primary: Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo — 6; 5 Participants — p=0.006

Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml

Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants

Primary: The Occurrence of Norovirus-associated Illness in Secretor Positive Participants Through Day 4 After Challenge. — 3; 2; 7; 0 Participants

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection — 7.8; 64.1; 72.7; 7.8 percentage of participants

Primary: Percentage of Participants With Seroconversion for Anti-poliovirus Types 1, 2 and 3 Neutralizing Antibody (Ab) — 99.2; 99.3; 100; 99.3 Percentage of participants

Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells

Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4

Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants

Primary: Number of Participants With Solicited Symptoms of Reactogenicity (Gastrointestinal [GI] and Systemic) — 20; 20; 2; 9 Participants

Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants

Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1 — 77.4; 63.5; 74.5; 85.7 percentage of participants

Primary: Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose. — 15; 54…

Primary: Frequency of Norovirus Gastroenteritis (NVG) — 5; 4 Participants